GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » Cyclically Adjusted Revenue per Share

AtriCure (AtriCure) Cyclically Adjusted Revenue per Share : $6.76 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is AtriCure Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AtriCure's adjusted revenue per share for the three months ended in Dec. 2023 was $2.294. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.76 for the trailing ten years ended in Dec. 2023.

During the past 12 months, AtriCure's average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AtriCure was 9.10% per year. The lowest was -7.80% per year. And the median was 5.05% per year.

As of today (2024-04-27), AtriCure's current stock price is $23.17. AtriCure's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $6.76. AtriCure's Cyclically Adjusted PS Ratio of today is 3.43.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AtriCure was 15.67. The lowest was 1.54. And the median was 5.48.


AtriCure Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for AtriCure's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AtriCure Cyclically Adjusted Revenue per Share Chart

AtriCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.11 5.20 5.68 6.21 6.76

AtriCure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.21 6.39 6.55 6.69 6.76

Competitive Comparison of AtriCure's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, AtriCure's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AtriCure's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AtriCure's Cyclically Adjusted PS Ratio falls into.



AtriCure Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AtriCure's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.294/129.4194*129.4194
=2.294

Current CPI (Dec. 2023) = 129.4194.

AtriCure Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.003 99.695 1.302
201406 0.988 100.560 1.272
201409 0.991 100.428 1.277
201412 1.092 99.070 1.427
201503 1.104 99.621 1.434
201506 1.193 100.684 1.533
201509 1.144 100.392 1.475
201512 1.170 99.792 1.517
201603 1.146 100.470 1.476
201606 1.256 101.688 1.599
201609 1.209 101.861 1.536
201612 1.294 101.863 1.644
201703 1.289 102.862 1.622
201706 1.401 103.349 1.754
201709 1.294 104.136 1.608
201712 1.410 104.011 1.754
201803 1.427 105.290 1.754
201806 1.558 106.317 1.897
201809 1.486 106.507 1.806
201812 1.449 105.998 1.769
201903 1.459 107.251 1.761
201906 1.578 108.070 1.890
201909 1.496 108.329 1.787
201912 1.605 108.420 1.916
202003 1.376 108.902 1.635
202006 0.980 108.767 1.166
202009 1.244 109.815 1.466
202012 1.307 109.897 1.539
202103 1.328 111.754 1.538
202106 1.585 114.631 1.789
202109 1.528 115.734 1.709
202112 1.586 117.630 1.745
202203 1.638 121.301 1.748
202206 1.850 125.017 1.915
202209 1.817 125.227 1.878
202212 1.917 125.222 1.981
202303 2.028 127.348 2.061
202306 2.181 128.729 2.193
202309 2.118 129.860 2.111
202312 2.294 129.419 2.294

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


AtriCure  (NAS:ATRC) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AtriCure's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=23.17/6.76
=3.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AtriCure was 15.67. The lowest was 1.54. And the median was 5.48.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AtriCure Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of AtriCure's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AtriCure (AtriCure) Business Description

Industry
Traded in Other Exchanges
N/A
Address
7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Executives
Karl S. Dahlquist officer: Chief Legal Officer 7555 INNOVATION WAY, MASON OH 45040
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy officer: Chief Scientific Officer 7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Tonya Austin officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick officer: Chief Financial Officer 7555 INNOVATION WAY, MASON OH 45040
Mark A Collar director 382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith officer: SVP of Sales and Marketing 7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera officer: VP; Product Development 7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky officer: SVP, Mktg & Business Develop 7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein director